{
    "Trade/Device Name(s)": [
        "EliA M2 Immunoassay",
        "EliA M2 Positive Control 100",
        "EliA M2 Positive Control 250"
    ],
    "Submitter Information": "Phadia US, Inc.",
    "510(k) Number": "K141375",
    "Predicate Device Reference 510(k) Number(s)": [
        "K052262"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DBM",
        "JJY"
    ],
    "Summary Letter Date": "December 22, 2014",
    "Summary Letter Received Date": "December 24, 2014",
    "Submission Date": "February 13, 2015",
    "Regulation Number(s)": [
        "21CFR866.5090",
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Antimitochondrial antibody immunological test system"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "IgG antibodies to M2 (mitochondrial antigen)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Phadia 100",
        "Phadia 250"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescence immunoassay",
        "Enzyme-linked immunosorbent assay (ELISA)"
    ],
    "Methodologies": [
        "Immunoassay",
        "Fluorescence detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for EliA M2 Immunoassay and positive controls for semi-quantitative measurement of IgG antibodies to M2 for primary biliary cirrhosis diagnosis",
    "Indications for Use Summary": "EliA M2 is intended for in vitro semi-quantitative measurement of IgG antibodies to M2 in human serum and plasma (heparin, EDTA) to aid in the clinical diagnosis of primary biliary cirrhosis, using Phadia 100 or Phadia 250 platforms; positive controls are for monitoring assay performance.",
    "fda_folder": "Immunology"
}